.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FF03_Durvalumab.Durvalumab .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FF03_Durvalumab.Durvalumab| name: | Durvalumab | |
| ATC code: | L01FF03 | route: | intravenous |
| compartments: | 2 | |
| dosage: | 1500 | mg |
| volume of distribution: | 5.6 | L |
| clearance: | 0.217 | L/h |
| other parameters in model implementation | ||
Durvalumab is a human monoclonal antibody that blocks programmed death-ligand 1 (PD-L1), thereby enhancing T-cell-mediated immune response against tumor cells. It is primarily used for the treatment of locally advanced or metastatic urothelial carcinoma and non-small cell lung cancer, and is approved for clinical use.
Population pharmacokinetics in adult cancer patients (including non-small cell lung cancer, urothelial carcinoma). Parameters reported for intravenous administration in adults.
Siu, L, et al., & Hong, DS (2020). Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors. Journal for immunotherapy of cancer 8(2) –. DOI:10.1136/jitc-2020-001095 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33037117